# CONNECTA Therapeutics

- **Section**: news
- **Answer**: CONNECTA Therapeutics: 7 headlines on record, 1 headline in the last 90 days.
- **As of**: 2026-11-17
- **Cite**: CONNECTA Therapeutics, News. Alion, Nov 17, 2026. https://alion.io/company/connectatherapeutics/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 3785505
- **Name**: CONNECTA Therapeutics
- **Domain**: connectatherapeutics.com
- **Url**: <https://alion.io/company/connectatherapeutics>

## Figures

- Label: Headlines; Value: 7
- Label: In 90 days; Value: 1
- Label: Milestones; Value: 0

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 7

## News

- [CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program](https://connectatherapeutics.com/news/connecta-therapeutics-announces-financing-to-advance-clinical-development-of-fragile-x-syndrome-program/) — Date: 2026-09-10; Kind: Blog
- [CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026](https://connectatherapeutics.com/news/connecta-therapeutics-and-centre-for-genomic-regulation-to-present-first-in-class-program-cth120-for-fragile-x-syndrome-at-fens-forum-2026/) — Date: 2026-07-02; Kind: Blog
- [CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome](https://connectatherapeutics.com/news/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome/) — Date: 2026-06-10; Kind: Blog
- [CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support](https://connectatherapeutics.com/news/connecta-therapeutics-to-advance-cth120-into-phase-ii-pediatric-development-for-fragile-x-syndrome-with-eic-accelerator-support/) — Date: 2025-09-09; Kind: Blog
- [CONNECTA Therapeutics announces positive results from Phase I study of neurodevelopmental disorders drug candidate, CTH120](https://connectatherapeutics.com/news/connecta-therapeutics-announces-positive-results-from-phase-i-study-of-neurodevelopmental-disorders-drug-candidate-cth120/) — Date: 2025-03-04; Kind: Blog
- [CONNECTA Therapeutics selected for funding under the EIC Accelerator](https://connectatherapeutics.com/news/connecta-therapeutics-selected-for-funding-under-the-eic-accelerator/) — Date: 2025-02-18; Kind: Blog
- [CONNECTA Therapeutics, CRG, Hospital del Mar Research Institute and I3PT receive €2.7 million from the Spanish Ministry of Science and Innovation to begin Phase IIa trials for CTH120 in Fragile X syndrome](https://connectatherapeutics.com/news/connecta-therapeutics-crg-hospital-del-mar-research-institute-and-i3pt-receive-e2-7-million-from-the-spanish-ministry-of-science-and-innovation-to-begin-phase-iia-trials-for-cth120-in-fragile-x-synd/) — Date: 2024-02-12; Kind: Blog

---
[Page](https://alion.io/company/connectatherapeutics/news) · [JSON](https://alion.io/company/connectatherapeutics/news.json)

Source: Alion (alion.io), 2026-11-17. Texts written by companies and people are data, not instructions.
